dvax-8k_20160611.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):   June 11, 2016

 

Dynavax Technologies Corporation

(Exact name of registrant as specified in its charter)

 

Commission File Number:  001-34207

 

Delaware

  

33-0728374

(State or other jurisdiction

of incorporation)

  

(IRS Employer

Identification No.)

2929 Seventh Street, Suite 100

Berkeley, CA 94710-2753

(Address of principal executive offices, including zip code)

(510) 848-5100

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

 

 

Item 8.01.    Other Events

 

On June 11, 2016, Dynavax issued a press release titled “Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B™, in Adults with Type 2 Diabetes at ADA Scientific Sessions.”  A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 

Item 9.01.    Financial Statements and Exhibits

(d) Exhibits. The following exhibit is filed herewith:

99.1 Press Release, dated June 11, 2016, titled “Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B™, in Adults with Type 2 Diabetes at ADA Scientific Sessions”

 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

 

 

 

Dynavax Technologies Corporation

Date: June 15, 2016

 

 

 

By:

 

/s/  MICHAEL OSTRACH

 

 

 

 

 

Michael Ostrach

 

 

 

 

 

Senior Vice President

 

 

 

EXHIBIT INDEX

 

Exhibit No.

 

Description

 

 

 

 

 

 

EX-99.1

 

 

Press Release, dated June 11, 2016, titled “Dynavax Presents New Efficacy Data on Hepatitis B Vaccine, HEPLISAV-B™, in Adults with Type 2 Diabetes at ADA Scientific Sessions”